Kuhn E, Sominsky L, Chitto M, Schwarz E, Moriarty T
Pharmaceuticals (Basel). 2024; 17(11).
PMID: 39598446
PMC: 11597390.
DOI: 10.3390/ph17111537.
Ahmed H, Bohmdorfer M, Jager W, Zeitlinger M
J Antimicrob Chemother. 2024; 80(2):363-371.
PMID: 39556193
PMC: 11787889.
DOI: 10.1093/jac/dkae412.
Buyukyanbolu E, Gill C, Genc L, Karakus M, Comert F, Otlu B
Eur J Clin Microbiol Infect Dis. 2024; 44(1):159-165.
PMID: 39546100
DOI: 10.1007/s10096-024-04990-w.
Jiao Y, Yan J, Sutaria D, Lu P, Vicchiarelli M, Reyna Z
Antimicrob Agents Chemother. 2024; 68(3):e0139423.
PMID: 38289076
PMC: 10916399.
DOI: 10.1128/aac.01394-23.
Haseeb A, Faidah H, Alghamdi S, Alotaibi A, Elrggal M, Mahrous A
Front Pharmacol. 2022; 13:964005.
PMID: 36210807
PMC: 9532942.
DOI: 10.3389/fphar.2022.964005.
Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose.
Zhao C, Chirkova A, Rosenborg S, Palma Villar R, Lindberg J, Hobbie S
J Antimicrob Chemother. 2022; 77(10):2718-2728.
PMID: 35849148
PMC: 9525081.
DOI: 10.1093/jac/dkac225.
Pharmacodynamic Thresholds for Beta-Lactam Antibiotics: A Story of Mouse Man.
Berry A, Kuti J
Front Pharmacol. 2022; 13:833189.
PMID: 35370708
PMC: 8971958.
DOI: 10.3389/fphar.2022.833189.
Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling.
Bilal H, Tait J, Lang Y, Zhou J, Bergen P, Peleg A
Antimicrob Agents Chemother. 2022; 66(3):e0220321.
PMID: 35041509
PMC: 8923196.
DOI: 10.1128/aac.02203-21.
Combating Multidrug-Resistant Bacteria by Integrating a Novel Target Site Penetration and Receptor Binding Assay Platform Into Translational Modeling.
Lang Y, Shah N, Tao X, Reeve S, Zhou J, Moya B
Clin Pharmacol Ther. 2021; 109(4):1000-1020.
PMID: 33576025
PMC: 10662281.
DOI: 10.1002/cpt.2205.
Influence of biofilm growth age, media, antibiotic concentration and exposure time on Staphylococcus aureus and Pseudomonas aeruginosa biofilm removal in vitro.
Chen X, Thomsen T, Winkler H, Xu Y
BMC Microbiol. 2020; 20(1):264.
PMID: 32831025
PMC: 7444035.
DOI: 10.1186/s12866-020-01947-9.
Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model.
Bilal H, Bergen P, Kim T, Chung S, Peleg A, Oliver A
Antimicrob Agents Chemother. 2019; 63(11).
PMID: 31427301
PMC: 6811397.
DOI: 10.1128/AAC.01293-19.
Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis Drugs.
Gumbo T, Alffenaar J
Clin Infect Dis. 2018; 67(suppl_3):S267-S273.
PMID: 30496455
PMC: 6260166.
DOI: 10.1093/cid/ciy608.
Pharmacodynamic Characterization of a Novel Odilorhabdin Antibiotic, NOSO-502, against Escherichia coli and Klebsiella pneumoniae in a Murine Thigh Infection Model.
Zhao M, Lepak A, Marchillo K, VanHecker J, Andes D
Antimicrob Agents Chemother. 2018; 62(9).
PMID: 29987156
PMC: 6125547.
DOI: 10.1128/AAC.01067-18.
Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model.
Landersdorfer C, Rees V, Yadav R, Rogers K, Kim T, Bergen P
Antimicrob Agents Chemother. 2018; 62(4).
PMID: 29437610
PMC: 5913933.
DOI: 10.1128/AAC.02055-17.
Identification of the Pharmacokinetics and Pharmacodynamic Driver of Iclaprim.
Park J, Craig W, Marchillo K, Huang D, Andes D
Antimicrob Agents Chemother. 2018; 62(4).
PMID: 29378717
PMC: 5913961.
DOI: 10.1128/AAC.02550-17.
Pharmacokinetics and Pharmacodynamics of Temocillin.
Alexandre K, Fantin B
Clin Pharmacokinet. 2017; 57(3):287-296.
PMID: 28849402
DOI: 10.1007/s40262-017-0584-7.
Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model.
Zhao M, Lepak A, Marchillo K, VanHecker J, Andes D
Antimicrob Agents Chemother. 2017; 61(7).
PMID: 28416552
PMC: 5487610.
DOI: 10.1128/AAC.00250-17.
Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.
Onufrak N, Forrest A, Gonzalez D
Clin Ther. 2016; 38(9):1930-47.
PMID: 27449411
PMC: 5039113.
DOI: 10.1016/j.clinthera.2016.06.015.
Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory.
Grupper M, Kuti J, Nicolau D
Clin Microbiol Rev. 2016; 29(4):759-72.
PMID: 27413094
PMC: 5010748.
DOI: 10.1128/CMR.00022-16.
Cefotaxime and Amoxicillin-Clavulanate Synergism against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Urinary Tract Infection.
Rossi B, Soubirou J, Chau F, Massias L, Dion S, Lepeule R
Antimicrob Agents Chemother. 2015; 60(1):424-30.
PMID: 26525800
PMC: 4704162.
DOI: 10.1128/AAC.02018-15.